Theravance Biopharma to Present New Data Highlighting in vitro Potency of VIBATIV(R) (telavancin) Against Gram-Positive Bacteria, Including MRSA, at 2015 ICAAC

Theravance Biopharma, Inc.

("Theravance Biopharma" or the "Company") today announced that data from studies of VIBATIV® (telavancin) will be presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Diego, CA, on September 17 - 21, 2015. New data on the in vitro potency of VIBATIV against isolates from a range of difficult-to-treat infections, including methicillin-resistant Staphylococcus aureus (MRSA), will be highlighted in several poster presentations at the conference. The presented findings further supplement the extensive and well-documented evidence demonstrating greater in vitro activity for VIBATIV against MRSA and other difficult-to-treat clinical pathogens as compared to antibiotics such as vancomycin, daptomycin and linezolid. Importantly, these presentations include demonstration of greater potency for VIBATIV against isolates from serious infection types with significant unmet medical need including biofilm-associated MRSA and infective endocarditis caused by MRSA, among others. Details of the VIBATIV poster presentations at ICAAC are as follows: Poster D-217: Evaluation of the Activity of Telavancin (TLV), Vancomycin (VAN), Teicoplanin (TEI), and Daptomycin (DAP) Combinations against Biofilm-producing Methicillin-resistant Staphylococcus aureus (MRSA) Session: Laboratory Workflow, Enteric Pathogens and Biofilms Friday, September 18, 2015, 12:00 - 2:00 p.m. Pacific Location: Exhibit Hall F Poster B-056: Efficacy of Telavancin (TLV) vs. Vancomycin (VAN) and Daptomycin (DAP) in Experimental Endocarditis (IE) due to Multi-Clonotype Methicillin-Resistant Staphylococcus aureus (MRSA) Strains Session: Existing Drugs Used in a New Context or Combination Friday, September 18, 2015, 12:00 - 2:00 p.m. Pacific Location: Exhibit Hall F Poster C-565: Activity of Telavancin against Gram-Positive Cocci from Canadian Hospitals Using Revised CLSI Guidelines: CANWARD 2013 and 2014 Session: In Vitro Activities of New Drugs and Inhibitors against Gram-Positives Saturday, September 19, 2015, 11:00 a.m. - 1: 00 p.m. Pacific Location: Exhibit Hall F Poster C-557: Update of Telavancin in vitro Activity Against a USA Collection of Gram-positive Clinical Isolates (2014) Causing Skin and Skin Structure Infections Session: In Vitro Activities of New Drugs and Inhibitors against Gram-Positives Saturday, September 19, 2015, 11:00 a.m. - 1: 00 p.m. Pacific Location: Exhibit Hall F VIBATIV is a bactericidal, once-daily, injectable lipoglycopeptide antibiotic with in vitro potency and a dual mechanism of action whereby telavancin both inhibits bacterial cell wall synthesis and disrupts bacterial cell membrane function. The drug's proven efficacy against difficult-to-treat Gram-positive infections has been demonstrated in several large, multinational registrational studies, which involved one of the largest cohorts of patients with MRSA infections studied to date. Additionally, there is extensive and well-documented evidence of the drug's in vitro potency and in vivo activity against a broad collection of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.